The immunocytochemical expression ofVE‐1 (BRAFV600E‐related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid‐based cytology

Autor: Maurizio Martini, Esther Diana Rossi, Teresa Musarra, Paola Lanza, Alfredo Pontecorvi, Patrizia Straccia, Chiara Brunelli, Celestino Pio Lombardi, Guido Fadda
Rok vydání: 2019
Předmět:
Male
Pathology
0302 clinical medicine
papillary
Cytology
80 and over
thyroid cancer
antibodies
Aged
80 and over
medicine.diagnostic_test
thyroid nodules
fine needle aspiration
Antibodies
Monoclonal
General Medicine
Middle Aged
cell block
Immunohistochemistry
Fine-needle aspiration
Thyroid Cancer
Papillary
030220 oncology & carcinogenesis
Liquid-based cytology
Monoclonal
papillary thyroid carcinoma
Female
Adult
Proto-Oncogene Proteins B-raf
Thyroid nodules
medicine.medical_specialty
Histology
Adolescent
Cytodiagnosis
monoclonal
030209 endocrinology & metabolism
Pathology and Forensic Medicine
Thyroid carcinoma
Young Adult
03 medical and health sciences
medicine
Humans
Neoplasm Invasiveness
Thyroid Neoplasms
BRAF V600E antibody (clone VE1)
Aged
business.industry
BRAF V600E antibody (clone VE1)
cell block
fine needle aspiration
papillary thyroid carcinoma
thyroid nodules
adolescent
adult
aged
aged
80 and over
antibodies
monoclonal
female
humans
immunohistochemistry
male
middle aged
mutation
neoplasm invasiveness
proto-oncogene proteins B-raf
thyroid cancer
papillary
thyroid neoplasms
young adult
cytodiagnosis
medicine.disease
Mutation
business
V600E
Immunostaining
Zdroj: Cytopathology. 30:460-467
ISSN: 1365-2303
0956-5507
DOI: 10.1111/cyt.12690
Popis: Background The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in cytology and cell block samples is rarely performed, and its diagnostic value in cytology has not been well established. In this study, we sought to determine if VE1 is suitable for fine needle aspiration (FNA) and cell block methods. Methods A total of 86 patients who had BRAF V600E mutations were investigated with molecular and immunocytochemical (ICC) analysis in 45 FNA and 41 cell blocks. In total, 83 (96.5%) patients underwent surgical treatment. Assessment of BRAF V600E mutation status was performed in 72 (83.7%) cases. Results Among the 72 cases analysed, 54 cases agreed (ICC+/BRAF+ or ICC-/BRAF-), seven cases were false positive (ICC+/BRAF-) and 11 cases were false negative (ICC-/BRAF+). False negative cases were not detected in the cell block method. The statistical analysis showed that sensitivity and specificity of ICC for detecting the BRAF V600E mutation were 61% and 77% in FNA samples and 100% and 73% in cell block. Conclusion The use of antibody VE-1 is a reliable method and a negative result of VE1 immunostaining might help to save time and money, restricting the molecular test to antibody-positive cases only. The identification of the aggressive variants of papillary carcinoma might be enabled by the expression of the antibody in neoplastic cells with tall cell features.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje